Fatty liver disease - non alcoholic to metabolic - A transition of concepts!!

被引:2
作者
Bawiskar, Nipun [1 ]
Acharya, Sourya [1 ]
Kumar, Sunil [1 ]
机构
[1] Deemed Univ, Datta Meghe Inst Higher Educ & Res, Jawaharlal Nehru Med Coll, Dept Med, Wardha, Maharashtra, India
关键词
Hepatic steatosis; MAFLD; metabolic dysregulation; obesity; RISK; ASSOCIATION; PREVALENCE; MORTALITY; FIBROSIS; NAFLD;
D O I
10.4103/jfmpc.jfmpc_1863_21
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Metabolic dysfunction associated fatty liver disease (MAFLD) was a concept suggested lately. Initially, the only criterion for the diagnosis of MAFLD was the absence of alcohol intake. With rising prevalence and studies assessing this condition, certain "positive criteria" were put forth. Experts from 22 countries proposed a simple yet comprehensive definition for the condition independent of other liver diseases. The presence of hepatic steatosis in addition to diabetes mellitus type 2, metabolic dysregulation, and obesity is generally observed. Criteria to define MAFLD-associated cirrhosis were also proposed. Reaching an agreement on MAFLD criteria will help define a protocol (for example: for International classification of Diseases (ICD) - coding), which will improve clinical care and advance the clinical and scientific field of liver research. As it is a condition that increases the risk of diabetes mellitus, chronic kidney disease (CKD), cirrhosis, hepatocellular carcinoma, and cardiac disorders it is important to recognize it at an early stage which makes it essential part of family medicine and primary care.
引用
收藏
页码:2857 / 2862
页数:6
相关论文
共 50 条
  • [1] Non alcoholic fatty liver disease and metabolic syndrome
    Paschos, P.
    Paletas, K.
    HIPPOKRATIA, 2009, 13 (01) : 9 - 19
  • [2] Non-Alcoholic Fatty Liver Disease in Cuba
    Castellanos-Fernandez, Marlen, I
    Crespo-Ramirez, Eduardo
    del Valle-Diaz, Sergio
    Barreto-Suarez, Eduardo
    Diaz-Elias, Javier O.
    Santalo-Rodriguez, Lorenzo
    Corrales-Alonso, Sahili
    Morales-Martinez, Ignacio
    Cedeno-Ramirez, Elisa
    Perez-Gonzalez, Teresita
    Gonzalez-Suero, Sila M.
    Ruenes-Domech, Caridad
    Infante-Velazquez, Mirtha
    Borges-Gonzalez, Susana A.
    Elvirez-Gutierrez, Angela
    Lazo-del Vallin, Sacha
    Villa-Jimenez, Oscar M.
    Labrada-Moreno, Liana M.
    MEDICC REVIEW, 2021, 23 (01) : 64 - 71
  • [3] Non Alcoholic Fatty Liver Disease (NAFLD) in Metabolic Syndrome (MetS)- A case control study
    Thomas, Julie Ann
    Acharya, Sourya
    Shukla, Samarth
    Thomas, Joel Joy
    Pratapa, Sree Karthik
    Hulkoti, Vidyashree
    MEDICAL SCIENCE, 2020, 24 (103) : 1490 - 1499
  • [4] Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome
    Grander, Christoph
    Grabherr, Felix
    Moschen, Alexander R.
    Tilg, Herbert
    VISCERAL MEDICINE, 2016, 32 (05) : 329 - 334
  • [5] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250
  • [6] Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations
    Milic, Sandra
    Lulic, Davorka
    Stimac, Davor
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (28) : 9330 - 9337
  • [7] Non-alcoholic fatty liver disease in Africa: a hidden danger
    Paruk, Imran M.
    Pirie, Fraser J.
    Motala, Ayesha A.
    GLOBAL HEALTH EPIDEMIOLOGY AND GENOMICS, 2019, 4 : e3
  • [8] Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease
    Tovoli, Francesco
    Ferri, Silvia
    Piscaglia, Fabio
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (32) : 3909 - 3914
  • [9] Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?
    Oikonomou, Dimitrios
    Georgiopoulos, Georgios
    Katsi, Vassiliki
    Kourek, Chris
    Tsioufis, Constantinos
    Alexopoulou, Alexendra
    Koutli, Evaggelia
    Tousoulis, Dimitrios
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (09) : 979 - 985
  • [10] Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes
    Li, Mian
    Zhao, Zhiyun
    Qin, Guijun
    Chen, Li
    Lu, Jieli
    Huo, Yanan
    Chen, Lulu
    Zeng, Tianshu
    Xu, Min
    Chen, Yuhong
    Wang, Tiange
    Wang, Shuangyuan
    Xu, Yiping
    Shi, Lixin
    Tang, Xulei
    Su, Qing
    Yu, Xuefeng
    Yan, Li
    Wan, Qin
    Chen, Gang
    Gao, Zhengnan
    Wang, Guixia
    Shen, Feixia
    Luo, Zuojie
    Zhang, Yinfei
    Liu, Chao
    Wang, Youmin
    Hu, Ruying
    Ye, Zhen
    Wu, Shengli
    Deng, Huacong
    Yang, Tao
    Li, Qiang
    Qin, Yingfen
    Mu, Yiming
    Zhao, Jiajun
    Ning, Guang
    Bi, Yufang
    Xu, Yu
    Wang, Weiqing
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 124